Skip to main content

Advertisement

SpringerLink
Log in

Current treatments in nonalcoholic steatohepatitis

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the United States secondary to the growing obesity epidemic. Although most patients with NAFLD do not develop progressive liver disease, the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH) are at risk for progression to cirrhosis and hepatocellular carcinoma, which necessitates appropriate follow-up and management. Unfortunately, proven treatment modalities for NASH that result in complete histopathologic regression of steatosis, inflammation, and fibrosis do not exist. Many therapeutic approaches to NAFLD management have been attempted, with varying degrees of success. However, most of these studies have been limited to small, single-center, uncontrolled trials. Based on our evolving understanding of the disease’s pathogenesis, it seems logical that a multidisciplinary approach addressing the underlying metabolic syndrome and the resultant intrinsic liver injury is necessary. Diet, exercise, surgical weight loss, diabetic medications, and hepatoprotective agents all have been studied and may serve as potential weapons in our armamentarium against this disease. Although most of these approaches have been studied as single-modality therapy, we believe that combination, multimodality therapy is required to treat this disease effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Beymer C, Kowdley KV, Larson AA, et al.: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003, 138:1240–1244.

    Article  PubMed  Google Scholar 

  2. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600–606.

    Article  PubMed  Google Scholar 

  3. Wanless IR, Lentz JS: Fatty liver steatosis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 11:74–80.

    Article  Google Scholar 

  4. Harrison SA, Day CP: Benefits of lifestyle modification in NAFLD. Gut 2007, In press.

  5. Harrison SA, Neuschwander-Tetri BA: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004, 8:861–879.

    Article  PubMed  Google Scholar 

  6. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ: The evolving role of leptin and adiponectinin chronic liver disease. Am J Gastroenterol 2006, 101:1–12.

    Article  Google Scholar 

  7. Pessayre D, Berson A, Fromenty B, Mansouri A: Mitochondria in steatohepatitis. Semin Liver Dis 2001, 21:57–69.

    Article  PubMed  CAS  Google Scholar 

  8. Harrison SA, Torgerson S, Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98:2042–2047.

    Article  PubMed  Google Scholar 

  9. Adams LA, Sanderson S, Lindor KD, Angulo P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132–138.

    Article  PubMed  Google Scholar 

  10. Adams LA, Lymp JF, Sauver J, et al.: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113–121.

    Article  PubMed  Google Scholar 

  11. Capristo E, Miele L, Forgione A, et al.: Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005, 9:265–268.

    PubMed  CAS  Google Scholar 

  12. Sato F, Tamura Y, Watada H, et al.: Effects of diet-induced moderate weight reduction on intrahepatic and intramyo-cellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrin Metab 2007, 92:3325–3329.

    Google Scholar 

  13. Fisler JS, Drenick EJ: Starvation and semistarvation diets in the management of obesity. Annu Rev Nutr 1987, 7:465–484.

    Article  PubMed  CAS  Google Scholar 

  14. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408–1413.

    PubMed  CAS  Google Scholar 

  15. Anderson T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991, 12:224–229.

    Article  Google Scholar 

  16. Okita M, Hayashi M, Sasagawa T, et al.: Effect of moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001, 17:542–547.

    Article  PubMed  CAS  Google Scholar 

  17. Thomas EL, Brynes AE, Hamilton G, et al.: Effect of nutritional counseling on hepatic, muscle, and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006, 12:5813–5819.

    PubMed  CAS  Google Scholar 

  18. Wang RT, Koretz RL, Yee HF: Is weight reduction an effective therapy for nonalcoholic fatty liver? A systemic review. Am J Med 2003, 114:554–559.

    Article  Google Scholar 

  19. Huang MA, Greenson JK, Chao C, et al.: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005, 100:1072–1081.

    Article  PubMed  Google Scholar 

  20. Musso G, Gambino R, De Michieli F, et al.: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909–916.

    Article  PubMed  CAS  Google Scholar 

  21. Cortez-Pinto H, Jesus L, Barros H, et al.: How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006, 25:816–823.

    Article  PubMed  CAS  Google Scholar 

  22. Sekiya M, Yahagi N, Matsuzaka T, et al.: Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529–1539.

    PubMed  CAS  Google Scholar 

  23. El-Badry AM, Moritz W, Contaldo C, et al.: Prevention of reperfusion injury and microcirculatory failure in macro-steatotic mouse liver by omega-3 fatty acids. Hepatology 2007, 45:841–845.

    Article  CAS  Google Scholar 

  24. Capanni M, Calella F, Biagini MR, et al.: Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143–1151.

    Article  PubMed  CAS  Google Scholar 

  25. Spadaro L, Magliocco O, Spampinato D, et al.: 738 omega-3 polyunsaturated fatty acids: a pilot trial in non-alcoholic fatty liver disease. J Hepatol 2006, 44:S264.

    Article  Google Scholar 

  26. Paniagua JA, Gallego de la Sacristana A, Romero I, et al.: Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007, 30:1717–1723.

    Article  PubMed  CAS  Google Scholar 

  27. Le KA, Tappy L, D’Alessio DA: Mitochondrial dysfunction and insulin resistance: a matter of lifestyle? Curr Opin Clin Nutr Metab Care 2007, 10:494–497.

    Article  PubMed  CAS  Google Scholar 

  28. Yancy WS, Olsen MK, Guyton JR, et al.: A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia. Ann Intern Med 2004, 140:769–777.

    PubMed  Google Scholar 

  29. Tendler D, Lin S, Yancy WS, et al.: The effect of low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007, 52:589–593.

    Article  PubMed  CAS  Google Scholar 

  30. Petersen KF, Dufour S, Belfroy D, et al.: Reversal of nonalcoholic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603–608.

    Article  PubMed  CAS  Google Scholar 

  31. Westerbacka J, Lammi K, Hakkinen AM, et al.: Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005, 90:2804–2809.

    Article  PubMed  CAS  Google Scholar 

  32. Suzuki A, Lindor K, St Saver J, et al.: Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005, 43:1060–1066.

    Article  PubMed  CAS  Google Scholar 

  33. Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413–419.

    Article  PubMed  CAS  Google Scholar 

  34. Harrison SA, Fincke C, Helinski D, et al.: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004, 20:623–628.

    Article  PubMed  CAS  Google Scholar 

  35. Assy N, Hussein O, Abassi Z: Weight loss induced by orlistat reverses fatty infiltration and improved hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007, 56:443–444.

    Article  PubMed  Google Scholar 

  36. Zelber-Sagi S, Kessler A, Brazowsky E, et al.: A double-blind randomized placebo-controlled trial of orlistat for treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639–644.

    Article  PubMed  CAS  Google Scholar 

  37. Harrison SA, Brunt EM, Fecht WJ, et al.: Orlistat in the treatment of overweight patients with nonalcoholic steatohepatitis (NASH): a multi-centered, randomized, prospective trial. Gastroenterology 2007, 4(Suppl 2):T1059.

    Google Scholar 

  38. Marubbio AT, Buchwald H, Schwartz MZ, Varco R: Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol 1976, 66:684–691.

    PubMed  Google Scholar 

  39. Campbell JM, Hunk TK, Karam JH, Forsham PH: Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977, 137:602–610.

    Article  PubMed  CAS  Google Scholar 

  40. Kral JG, Thung SN, Biron S, et al.: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004, 135:48–58.

    Article  PubMed  Google Scholar 

  41. Dixon JB, Bhathal PS, Hughes NR, et al.: Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647–1654.

    Article  PubMed  Google Scholar 

  42. Klein S, Mittendorfer B, Eagon C, et al.: Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006, 130:1564–1572.

    Article  PubMed  CAS  Google Scholar 

  43. Barker KB, Palekar NA, Bowers SP, et al.: Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368–373.

    Article  PubMed  Google Scholar 

  44. Furuya CK, de Oliveira CP, de Mello ES, et al.: Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007, 22:510–514.

    Article  PubMed  CAS  Google Scholar 

  45. Lutchman G, Promrat K, Kleiner DE, et al.: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histologic improvement. Clin Gastroenterol Hepatol 2006, 4:1048–1052.

    Article  PubMed  CAS  Google Scholar 

  46. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008–1017.

    PubMed  CAS  Google Scholar 

  47. Belfort R, Harrison SA, Brown K, et al.: A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:15–25.

    Article  Google Scholar 

  48. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  49. Lin HZ, Yang SQ, Chuckaree C, et al.: Metformin reverses fatty liver disease in obese leptin-deficient mice. Nat Med 2000, 6:998–1003.

    Article  PubMed  CAS  Google Scholar 

  50. Marchensini G, Bianchi G, Tomassetti S, et al.: Metformin in non-alcoholic steatohepatitis. Lancet 348, 2001:893–894.

    Article  Google Scholar 

  51. Uygun A, Kadayifci A, Isik AT, et al.: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537–544.

    Article  PubMed  CAS  Google Scholar 

  52. Bugianesi E, Gentilcore E, Manini R, et al.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082–1090.

    Article  PubMed  CAS  Google Scholar 

  53. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al.: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169–2176.

    Article  PubMed  CAS  Google Scholar 

  54. Harrison SA, Torgerson S, Hayashi P, et al.: Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485–2490.

    Article  PubMed  CAS  Google Scholar 

  55. Yakaryilmaz F, Guliter S, Savas B, et al.: Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007, 37:229–235.

    Article  PubMed  CAS  Google Scholar 

  56. Federico A, Trappoliere M, Tuccillo C, et al.: A new silybin-vitamin E-phopholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006, 55:901–902.

    Article  PubMed  CAS  Google Scholar 

  57. Abdelmalek MF, Angulo P, Jorgenssen R, et al.: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96:2711–2717.

    Article  PubMed  CAS  Google Scholar 

  58. Pamuk GE, Sonsuz A: N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003, 18:220–221.

    Article  Google Scholar 

  59. Lindor KD, Kowdley KV, Heathcote EJ, et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770–778.

    Article  PubMed  CAS  Google Scholar 

  60. Adams LA, Zeine CO, Angulo P, et al.: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365–2368.

    Article  PubMed  CAS  Google Scholar 

  61. Satapathy SK, Sakhuja P, Malhotra V, et al.: Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 22:634–638.

    Google Scholar 

  62. Browning JD: Statins and hepatic steatosis: perspectives from the Dallas heart study. Hepatology 2006, 44:466–471.

    Article  PubMed  CAS  Google Scholar 

  63. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al.: A pilot study of atorvastatin treatment in dyslipdemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643–1647.

    Article  PubMed  CAS  Google Scholar 

  64. Ekstedt M, Franzen LE, Mathiesen UL, et al.: Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007, 47:135–141.

    Article  PubMed  CAS  Google Scholar 

  65. Hirose A, Ono M, Saibara T, et al.: Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375–1381.

    Article  PubMed  CAS  Google Scholar 

  66. Yokohama S, Yoneda M, Haneda M: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222–1225.

    Article  PubMed  CAS  Google Scholar 

  67. Yokohama S, Tokusashi Y, Nakamura K, et al.: Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12:322–326.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX, 78234, USA

    Stephen A. Harrison

Authors
  1. Dawn M. Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen A. Harrison.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torres, D.M., Harrison, S.A. Current treatments in nonalcoholic steatohepatitis. Curr Treat Options Gastro 10, 425–434 (2007). https://doi.org/10.1007/s11938-007-0042-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-007-0042-y

Keywords

Search

Navigation